H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Rapport Therapeutics, Inc. today and set a price target of $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors, including clear progress advancing RAP-219 into a well-defined Phase 3 program for focal onset seizures and multiple value-creating catalysts in 2026. He points to supportive Phase 2a data showing substantial seizure reduction and meaningful seizure freedom rates, alongside an ongoing Phase 2 bipolar mania trial that is designed to optimize titration for rapid yet safe symptom control.
Tsao also highlights the strengthening external backdrop, with recent positive epilepsy data from peers reinforcing confidence in the therapeutic area and potential for RAP-219 to become a competitive player. In addition, he views the new China partnership with Tenacia, which delivers upfront capital plus milestone and royalty potential, as strategically important non-dilutive funding that extends Rapport’s opportunity set and underpins his favorable risk‑reward assessment.
In another report released on March 9, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.